MetaADEDB 2.0 @ LMMD
Breast cancer stage III
(UMLS:C4721421)
UMLS ID:
C4721421
MeSH ID:
N/A
Synonym(s)
1.
Breast cancer stage III
2.
Breast Cancer Stage III
3.
breast cancer stage iii
4.
breast cancer, stage III
5.
stage III breast cancer
6.
stage iii breast cancer
Associated Drug(s)
NameNumber of ReportsReference(s)Data Source
1NorgestrelFAERS: 11OFFSIDES
US FAERS
2Raloxifene HydrochlorideFAERS: 9US FAERS
3Fingolimod HydrochlorideFAERS: 8US FAERS
4Medroxyprogesterone AcetateFAERS: 4OFFSIDES
US FAERS
5VareniclineFAERS: 4US FAERS
6Estrogens, Conjugated (USP)FAERS: 3OFFSIDES
US FAERS
7OmeprazoleFAERS: 3US FAERS
8CitalopramFAERS: 2US FAERS
9LosartanFAERS: 2US FAERS
10TeriparatideFAERS: 2US FAERS
11AlendronateFAERS: 1US FAERS
12ClomipheneFAERS: 1US FAERS
13EstradiolFAERS: 1US FAERS
14Glatiramer AcetateFAERS: 1OFFSIDES
US FAERS
15LetrozoleFAERS: 1US FAERS
16LosartanFAERS: 1US FAERS
17MeperidineFAERS: 1US FAERS
18MeperidineFAERS: 1US FAERS
19OndansetronFAERS: 1US FAERS
20PregabalinFAERS: 1US FAERS
21ProgesteroneFAERS: 1OFFSIDES
US FAERS
22QlairaFAERS: 1US FAERS
23QsymiaFAERS: 1US FAERS
24Raloxifene HydrochlorideFAERS: 1OFFSIDES
US FAERS
25RisperidoneFAERS: 1US FAERS
26Sitagliptin PhosphateFAERS: 1US FAERS
27SumatriptanFAERS: 1US FAERS
28Tiotropium BromideFAERS: 1US FAERS
29apremilastFAERS: 1US FAERS
30mirabegronFAERS: 1US FAERS
31testosterone undecanoateFAERS: 1US FAERS
32tofacitinibFAERS: 1US FAERS
33BeclomethasoneOFFSIDES
34CilazaprilOFFSIDES
35D-GalactosamineOFFSIDES
36DiphenhydramineOFFSIDES
37EphedrineOFFSIDES
38LeflunomideOFFSIDES
39MedroxyprogesteroneOFFSIDES
40MercaptopurineOFFSIDES
41PramipexoleOFFSIDES
42Zoledronic AcidOFFSIDES
43dihydrocodeineOFFSIDES
44mecobalaminOFFSIDES
45prednisolone acetateOFFSIDES
46rofecoxibOFFSIDES
47tizanidineOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.